Protagonist Therapeutics Inc
PTGX80.220USD
+0.020+0.02%
收盘 01/09, 16:00（美东）报价延迟15分钟
5.01B总市值
103.29市盈率 TTM
关于 Protagonist Therapeutics Inc 公司
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
Protagonist Therapeutics Inc简介
公司代码PTGX
公司名称Protagonist Therapeutics Inc
上市日期Aug 11, 2016
CEOPatel (Dinesh V)
员工数量126
证券类型Ordinary Share
年结日Aug 11
公司地址7707 Gateway Blvd Ste 140
城市NEWARK
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编94560-1160
电话15104740170
网址https://www.protagonist-inc.com/
公司代码PTGX
上市日期Aug 11, 2016
CEOPatel (Dinesh V)
Protagonist Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
313.16K
-440.00%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+14147.00%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+10725.00%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-1756.00%
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
--
-5130.00%
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Ms. Sarah A. O'Dowd
Ms. Sarah A. O'Dowd
Independent Director
Independent Director
--
-5130.00%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Corey Davis, Ph.D.
Mr. Corey Davis, Ph.D.
IR Contact Officer
IR Contact Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
313.16K
-440.00%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+14147.00%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+10725.00%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-1756.00%
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
--
-5130.00%
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月19日 周三
更新时间: 11月19日 周三
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
12.83%
Farallon Capital Management, L.L.C.
9.91%
RTW Investments L.P.
9.21%
The Vanguard Group, Inc.
6.79%
State Street Investment Management (US)
5.06%
其他
56.19%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
12.83%
Farallon Capital Management, L.L.C.
9.91%
RTW Investments L.P.
9.21%
The Vanguard Group, Inc.
6.79%
State Street Investment Management (US)
5.06%
其他
56.19%
股东类型
持股股东
占比
Investment Advisor
39.24%
Investment Advisor/Hedge Fund
36.00%
Hedge Fund
27.18%
Research Firm
5.73%
Venture Capital
4.41%
Private Equity
1.74%
Pension Fund
1.09%
Individual Investor
1.01%
Bank and Trust
0.33%
机构持股
更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
565
72.46M
115.91%
-7.78M
2025Q3
551
71.95M
115.09%
-3.63M
2025Q2
533
68.00M
109.30%
-9.94M
2025Q1
541
67.25M
108.51%
-8.96M
2024Q4
503
65.58M
106.87%
-12.21M
2024Q3
480
64.24M
108.98%
-11.36M
2024Q2
419
61.14M
104.21%
-15.61M
2024Q1
412
61.98M
106.36%
-12.46M
2023Q4
402
59.53M
103.21%
-16.02M
2023Q3
400
59.06M
102.70%
-14.36M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
8.02M
12.83%
-434.20K
-5.13%
Sep 30, 2025
Farallon Capital Management, L.L.C.
6.20M
9.91%
+24.00K
+0.39%
Sep 30, 2025
RTW Investments L.P.
5.76M
9.21%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
4.25M
6.79%
-101.37K
-2.33%
Sep 30, 2025
State Street Investment Management (US)
3.17M
5.06%
-41.75K
-1.30%
Sep 30, 2025
BVF Partners L.P.
2.56M
4.1%
-650.13K
-20.25%
Sep 30, 2025
Johnson & Johnson Innovation-JJDC, Inc.
2.45M
3.92%
--
--
Sep 30, 2025
Wellington Management Company, LLP
1.91M
3.05%
+870.71K
+83.90%
Sep 30, 2025
UBS Financial Services, Inc.
1.89M
3.03%
-608.94K
-24.35%
Sep 30, 2025
Deep Track Capital LP
1.72M
2.74%
-1.53M
-47.14%
Sep 30, 2025
查看更多
持股ETF
更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
Invesco S&P SmallCap Health Care ETF
2.82%
Invesco S&P SmallCap 600 Pure Growth ETF
2.71%
Invesco Dorsey Wright Healthcare Momentum ETF
2.33%
ALPS Medical Breakthroughs ETF
1.99%
ETC 6 Meridian Small Cap Equity ETF
1.56%
State Street SPDR S&P Biotech ETF
1.44%
Cambria Value and Momentum ETF
1.16%
Invesco S&P SmallCap Momentum ETF
1%
Virtus LifeSci Biotech Clinical Trials ETF
0.94%
Direxion Daily S&P Biotech Bull 3X Shares
0.88%
查看更多
Invesco S&P SmallCap Health Care ETF
占比2.82%
Invesco S&P SmallCap 600 Pure Growth ETF
占比2.71%
Invesco Dorsey Wright Healthcare Momentum ETF
占比2.33%
ALPS Medical Breakthroughs ETF
占比1.99%
ETC 6 Meridian Small Cap Equity ETF
占比1.56%
State Street SPDR S&P Biotech ETF
占比1.44%
Cambria Value and Momentum ETF
占比1.16%
Invesco S&P SmallCap Momentum ETF
占比1%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.94%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.88%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Protagonist Therapeutics Inc的前五大股东是谁？
Protagonist Therapeutics Inc 的前五大股东如下：
BlackRock Institutional Trust Company, N.A.持有股份：8.02M，占总股份比例：12.83%。
Farallon Capital Management, L.L.C.持有股份：6.20M，占总股份比例：9.91%。
RTW Investments L.P.持有股份：5.76M，占总股份比例：9.21%。
The Vanguard Group, Inc.持有股份：4.25M，占总股份比例：6.79%。
State Street Investment Management (US)持有股份：3.17M，占总股份比例：5.06%。
BlackRock Institutional Trust Company, N.A.持有股份：8.02M，占总股份比例：12.83%。
Farallon Capital Management, L.L.C.持有股份：6.20M，占总股份比例：9.91%。
RTW Investments L.P.持有股份：5.76M，占总股份比例：9.21%。
The Vanguard Group, Inc.持有股份：4.25M，占总股份比例：6.79%。
State Street Investment Management (US)持有股份：3.17M，占总股份比例：5.06%。
Protagonist Therapeutics Inc的前三大股东类型是什么？
Protagonist Therapeutics Inc 的前三大股东类型分别是：
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
RTW Investments L.P.
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
RTW Investments L.P.
有多少机构持有Protagonist Therapeutics Inc(PTGX)的股份？
截至2025Q4，共有565家机构持有Protagonist Therapeutics Inc的股份，合计持有的股份价值约为72.46M，占公司总股份的115.91%。与2025Q3相比，机构持股有所增加，增幅为0.82%。
哪个业务部门对Protagonist Therapeutics Inc的收入贡献最大？
在--，--业务部门对Protagonist Therapeutics Inc的收入贡献最大，创收--，占总收入的--%。
